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Abstract
Background With limited healthcare resources available,
cost-effective provision of dialysis to patients with end-
stage renal disease (ESRD) is important.
Objectives To assess the cost-effectiveness of varying
levels of peritoneal dialysis (PD) use versus current prac-
tice among incident ESRD patients requiring dialysis.
Methods A Markov model was developed to investigate
the cost-effectiveness of increasing uptake of PD to 39 and
50 % versus current practice of 22 % PD from a UK
National Health Service perspective for the year of
2013–2014. A scenario with 5 % PD was also considered.
Sensitivity analyses were performed.
Results Five- and 10-year discounted total costs and qual-
ity-adjusted life years (QALYs) per patient for the current
scenario (22 % PD) were £96,307 and 2.104, and £133,339
and 3.301, respectively. Use of PD in 39 % of patients
resulted in 5- and 10-year total per-patient cost savings of
£3,180 and £4,102 versus current usage alongside total per-
patient QALY increases of 0.017 and 0.020. Use of PD in
50 % of patients resulted in 5- and 10-year per-patient cost
savings of £5,238 and £6,758 versus current usage alongside
per-patient QALY increases of 0.029 and 0.033. Thus,
increasing use of PD was associated with marginally better
outcomes and lower costs. Cost savings were driven by lower
treatment costs and reduced transport requirements for PD
versus haemodialysis. Reducing PD use was associated with
higher costs and a small reduction in QALYs.
Conclusions These findings suggest increasing PD use
among incident dialysis patients would be cost-effective,
associated with reduced costs and potential modest
improvements in quality of life.
Key Points for Decision Makers
Increasing peritoneal dialysis (PD) usage among
incident patients with end-stage renal disease
(ESRD) requiring dialysis has the potential to result
in significant cost savings.
The possible clinical benefits and improvements in
patient quality of life associated with PD could also
reduce the burden of disease to the patient.
Implementing the use of PD as a first choice dialysis
modality among appropriate patients could be a
positive step towards supporting the National Health
Service (NHS) QIPP (Quality, Innovation,
Productivity and Prevention) programme in its aims
to reduce costs while improving the quality and
delivery of patient care.
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1 Introduction
People with end-stage renal disease (ESRD) require renal
replacement therapy (RRT) in the form of dialysis or kid-
ney transplant to sustain life. Due to ageing populations
and increased risk factors such as diabetes mellitus and
hypertension [1], the global prevalence of ESRD has been
increasing and thus is a significant public health concern.
In the European Union, the annual dialysis population
growth rate in 2012 was approximately 2 % [2]. In the UK,
approximately 55,000 adult patients received RRT in 2012
[3] with 6,891 commencing RRT [4]. The RRT population
represents approximately 2 % of the total chronic kidney
disease (CKD) population [5], but accounts for half of the
estimated £1.45 billion spent by the English National
Health Service (NHS) in 2009–2010 for care of CKD
(approximately 1.3 % of total NHS spending for that year)
[5].
The two main types of dialysis modality are haemodi-
alysis (HD) and peritoneal dialysis (PD). PD is home-
based, administered either by a cycler whilst asleep
[automated PD (APD)] or manually [continuous ambula-
tory PD (CAPD)]. HD is usually administered in a hospital
or satellite unit, three times per week, and sometimes at
home. As a home-based therapy, PD is associated with
fewer travel requirements, less exposure to hospital
pathogens and improved patient control. Factors deter-
mining choice of modality include availability of options,
clinical contraindications and, importantly, patient prefer-
ence [6]. Although evidence suggests that 50 % of patients
would choose PD where possible [7], the use of PD in the
UK has been decreasing over the last decade [8, 9]. In
2012 in the UK, approximately 22 % of incident dialysis
patients and 14 % of prevalent dialysis patients used PD
[3, 4].
The National Institute for Health and Care Excellence
(NICE) guidance for England and Wales, which is pro-
duced to support people in making informed decisions
about RRT, recommends that PD should be considered as
the first choice of dialysis modality in adult patients
without significant associated comorbidities [6]. The
guidance advises that offering PD where suitable gives
patients more choice and flexibility and can lead to short-
term survival benefit and improved preservation of residual
renal function [10]. Currently, the UK NHS is undergoing
an extensive overhaul; an integral part of this reform is the
QIPP (Quality, Innovation, Productivity and Prevention)
programme, which aims to improve quality and delivery of
NHS care while reducing costs and achieve £20 billion of
efficiency savings by 2015 [11]. A national costing report
on the prevalent dialysis population published by NICE in
2011 suggests that annual savings of approximately £20
million could be made nationally if 39 % of dialysis
patients were to receive PD [12]. It is believed that
exploring which dialysis modality or modalities should be
chosen to achieve best outcomes for incident ESRD
patients is valuable.
This study aimed to determine the cost-effectiveness of
varying levels of PD use versus current practice among
incident dialysis patients to build on a similar analysis
conducted by NICE among prevalent dialysis patients [10].
The 5- and 10-year cost-effectiveness, in terms of cost per
quality-adjusted life-year (QALY), of increasing the pro-
portion of incident patients on PD to 39 and 50 %, or of
assuming only 5 % use of PD, compared with typical UK
current practice [22 % PD, 78 % in-centre HD (ICHD)
conventional] was investigated from the UK payer
perspective.
2 Methods
A Markov model was developed to assess the relative cost-
effectiveness of different dialysis modality distribution
scenarios versus current practice. The model considers a
hypothetical adult incident patient cohort with ESRD
requiring dialysis and adopts a UK payer perspective. Costs
and benefits are discounted at a rate of 3.5 % per annum in
line with current UK Treasury guidance [13]. Total costs
and QALYs per-patient and incremental cost-effectiveness
ratios (ICERs) (expressed as cost per incremental QALY)
over 5- and 10-year time horizons are estimated. Sensitivity
analyses were conducted to test the robustness of our
model conclusions.
2.1 Patient Distribution and Comparators
Default data for the reference scenario’s modality distri-
bution (22 % PD, 78 % ICHD conventional), representing
UK current practice, were sourced from the UK Renal
Registry 16th Annual Report [4]. The UK Renal Registry,
which automatically collects data quarterly from UK renal
unit databases, was selected as an independent source of
data and analysis. The baseline distribution of PD is: 50 %
CAPD and 50 % APD [3]. This breakdown is assumed to
be consistent in all scenarios. Alternative scenarios to UK
current practice included: Scenario 1, 39 % PD and 61 %
ICHD conventional (39 % PD was used in the recent
economic evaluation by NICE [10]); Scenario 2, 50 % PD,
50 % ICHD conventional (evidence suggests 50 % of
patients would choose PD where possible [7] and some UK
centres achieve this level of PD use [4]); Scenario 3, 5 %
PD and 95 % ICHD conventional (chosen to see the effect
of limited use of PD as seen in some UK centres [4]).
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2.2 Model Structure
The Markov model was developed in Microsoft Excel
2010. Markov models are particularly suited to modelling
chronic conditions such as ESRD [14]. The model com-
prises a number of discrete health states, between which
patients can transition. These states include PD, ICHD,
home HD (HHD) and transplant (Fig. 1). The total time
horizon of the model is divided into ‘cycles’ of time
between which patient transitions can occur. To ensure
consistency in calculations, the model adopts 28-day
cycles. Short model cycles, which have been used in pre-
vious, similar economic evaluations, are favoured since
they increase the model’s sensitivity to likely changes in
health states [15, 16]. In the model, from one cycle to the
next, the patient may stay on their current modality, switch
to a different modality, have a kidney transplant or die.
Whilst on dialysis, patients face a probability of compli-
cations that is dependent only on their current dialysis
modality. Patients can die in any state and only one
movement is allowed per cycle. Once a patient dies, they
no longer accrue costs and QALYs.
2.3 Model Inputs
2.3.1 Clinical Data
Relevant clinical data were identified in previous economic
evaluations and NICE publications. Systematic reviews that
had been previously conducted to populate a number of
similar models were identified, and an additional rapid lit-
erature review was performed to identify studies and data
published in the interim. Where more than one relevant data
source was identified, to be conservative, the one that gen-
erated a higher incremental cost effectiveness ratio (ICER)
was used. The clinical input data and sources of the data are
shown in Table 1 and are described in more detail below.
2.3.2 Survival
Survival was estimated based on data from the ERA-EDTA
Annual Report 2009 [17], which relates to European inci-
dent patients on dialysis, and was used because the UK
Renal Registry reports do not provide such detailed infor-
mation on patient survival. The age and gender distribution
of patients in the UK was found to be comparable to those
in patients in the US and in other European countries based
on data published by the USRDS (US) [18] and ERA-
EDTA (Europe) [19] registries. It was therefore deemed
appropriate to use European ERA-EDTA registry data to
approximate the UK population in this analysis. The sur-
vival curves published in the ERA-EDTA report permit
parametric modelling of survival, whereas the UK Renal
Registry’s summary statistics do not. Five-year survival
curves for HD and PD patients were digitised and the data
obtained converted into a patient-level data set and ana-
lysed in the statistical package, R [20]. Further information
regarding the R survreg function is provided as Electronic
Supplementary Material accompanying this article. In
order to extrapolate PD and HD survival beyond 5 years,
parametric survival models were fitted to the data. Since
extrapolating the available 5-year HD and PD data beyond
10 years would cause more uncertainty and as a result be
less reliable, it was assumed that there were no differences
in mortality rates between modalities after 10 years. This is
in line with the review paper by Chiu [21], which reported
that ‘virtually all the recent observational studies from
different parts of the world consistently show that long-
term survival of HD and PD patients is remarkably simi-
lar’. Average extrapolated mortality rates were used across
all dialysis modalities beyond 10 years. Survival of
patients post-transplant was modelled using 5-year sum-
mary survival data for the 2005–2007 transplant cohort
from NHS blood and transplant’s activity report for
2012/2013 [22].
Fig. 1 Model flow diagram. One-way arrows indicate that patients
can move in one direction; two-way arrows indicate that patients can
move in either direction. Each dialysis modality is a separate health
state in the model, as follows: in-centre haemodialysis (ICHD)
conventional = hospital or satellite; home haemodialysis (HHD)
conventional; PD = continuous ambulatory peritoneal dialysis
(CAPD) or automated peritoneal dialysis (APD); transplant (transient
health state); post-transplant. Patients can die from any of the model’s
health states. The absorbing death state is not shown in this diagram
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Table 1 Clinical input data
Clinical parameter Value (range) Parameter
distribution
Data sources
HD exponential model intercept 1.98 (1.49–2.48) Lognormal ERA-EDTA survival data§ [17]
PD Weibull model intercept 1.92 (1.44–2.40) Lognormal
PD Weibull scale 0.82 (0.62–1.03) Lognormal
Hazard ratio to reflect an incident cohort 1.06 (0.80–1.33) Lognormal
Adjusting life to its quality: baseline utility values for patients in all health states
ICHD conventional (hospital and satellite) 0.56 (0.49–0.62) Beta Liem [28]
HHD conventional 0.69 (0.52–0.86) Beta deWit, Liem} [28, 29]
PD 0.58 (0.50–0.67) Beta Liem [28]
Transplant and post-transplant 0.81 (0.72–0.90) Beta Liem [28]
Dialysis modality switching assumptions: 28-day probability of switching modalities (incident population): %
HD to PD
0–6 months 3.58 (2.69–4.48) Beta Johnson [54]
7–12 months 0.08 (0.06–0.10)
13–18 months 0.08 (0.06–0.10)
19? months 0.08 (0.06–0.10)
PD to HD
0–6 months 2.61(1.96–3.26) Beta Baxter UK hospital data
7–12 months 1.13 (0.85–1.41)
13–18 months 0.78 (0.58–0.97)
19? months 0.31 (0.23–0.39)
ICHD to HHD
0–6 months 0.05 (0.04–0.06) Beta Assumption
7–12 months 0.05 (0.04–0.06)
13–18 months 0.03 (0.02–0.04)
19? months 0
HHD to ICHD
0–6 months 0.38 (0.29–0.48) Beta McFarlane [55]
7–12 months 0.38 (0.29–0.48)
13–18 months 0.38 (0.29–0.48)
19? months 0.38 (0.29–0.48)
Dialysis complications: 28-day probability of all-cause hospitalisation: %
ICHD conventional (hospital and satellite)
Year one 7.05 (5.29–8.81) Beta FHN trial [31]
Subsequent years 4.86 (3.65–6.08) Based on Arora [32]
HHD conventional
Year one 5.35 (4.01–6.68) Beta Rocco [56]
Subsequent years 3.68 (2.77–4.61) Based on Arora [32]
All PD modalities
Year one and subsequent years 7.05 (5.29–8.81) Beta Based on Lafrance [30, 31]
Breakdown of transplant type by donor: %
Living 36 (27.0–45.0) Dirichlet NHS Blood and Transplant Activity
Report 2012/2013 [22]Donor after brain death 39 (29.3–48.8)
Donor after cardiac death 25 (18.8–31.3)
Annual transplant probability: %
All patients 9 (7–11) Beta UK Renal Registry report data [57, 58]
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2.3.3 Quality-of-Life
Dialysis modality has the potential to impact upon patients’
quality-of-life (QoL). It has been reported that PD patients
have less illness intrusion, better renal care and higher
satisfaction, while HD patients have better staff and social
interaction and less fear of isolation [23–27]. The model
includes the utility of patients that varied between different
dialysis modalities and between patients on dialysis and
those receiving a kidney transplant. A systematic review
and meta-analysis conducted by Liem [28] was used as the
main source of utility values for the model; this was also
used in NICE clinical guideline (CG) 125. The utility value
assigned to patients receiving HHD was based on the
combined approach of NICE CG 125 [6] and NHS
CEP10063 [16]. The utility value assigned to ICHD con-
ventional from the Liem study [28] was multiplied by a
ratio of limited care HD to HD conventional utility scores
taken from the study by de Wit [29] to estimate a utility
value for conventional HHD.
2.3.4 Transition Probabilities
Patients may change dialysis modalities because of com-
plications and changes in preference or living conditions.
Estimated transition probabilities for the model are shown
in Table 1. When patients change dialysis modality they
are redistributed according to the baseline distribution of
the modality to which they change. For example, if a
patient moves from HD to PD, whether they move to APD
or CAPD is dependent on how PD patients are distributed
between these modalities at baseline (CAPD = 50 %;
APD = 50 %). The probability of a patient staying in the
same modality from one cycle to the next is taken to be
equal to 1 minus the probability that they move. Following
a transplant, all patients move to the post-transplant state
where they stay until graft failure/death. If graft failure
occurs, the patient’s subsequent dialysis setting is depen-
dent on the scenario’s baseline patient distribution.
2.3.5 Dialysis Complications
Patients undergoing dialysis may experience complica-
tions. The model looks specifically at all-cause hospitali-
sations as an encompassing approach. Since no studies
reporting all-cause hospitalisation probabilities in patients
on PD in the UK were available, to be conservative, it was
assumed that the rate was the same as for HD [30, 31]
(Table 1). All-cause hospitalisation probabilities in sub-
sequent years were calculated by applying a ratio of first-
year to subsequent-year hospitalisation rates derived from
the study by Arora [32]. In HD patients, hospitalisation
rates in subsequent years are 30 % lower than in the first
year, whereas for PD patients hospitalisations occur at the
same rate in subsequent years as in the first year.
2.3.6 Cost Data
In line with the UK National Health Spending perspective,
the model included the following important cost
Table 1 continued
Clinical parameter Value (range) Parameter
distribution
Data sources
Annual graft failure probability by donor type
Living 0.03 (0.03–0.04) Beta NHS Blood and Transplant Activity
Report 2012/2013 [22]Donor after brain death 0.06 (0.06–0.07)
Donor after cardiac death 0.08 (0.07–0.10)
Weighted average 0.05
Annual access failure probability: %
HD vascular access 10 (7.5–12.5) Beta Xue [33]
ESRD end-stage renal disease, HHD home haemodialysis, ICHD in-centre haemodialysis, PD peritoneal dialysis
 Variables were varied according to published ranges or by ±25 % for those variables without such information. Published confidence intervals
were available for the transplant graft failure rates [59], certain switching rate inputs [45] and the quality of life values [28]
 The distributions selected are widely believed to be appropriate choices for the model parameters and reflect best practice. The beta distribution
is a suitable choice for probability parameters (percentages or proportions) since it is defined on the interval [0, 1]. The Dirichlet distribution,
used for the breakdown of transplants by donor type, is an extension of the beta distribution, which can be used in the case of several mutually
exclusive categories. The lognormal distribution was selected for survival parameters since it constrains parameters to positive values
§ Survival parameters correspond to distributions embedded in a general location-scale family. For more information, please see the R survreg
function support pages provided as additional electronic supplementary material
} Ratio of limited care HD to conventional HD utility scores from deWit [29] is applied to the HD value from Liem [28] [0.56 9 (0.81/
0.66) = 0.69]
 Assumed to be equal to HD—conservative assumption based on Lafrance [30]
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components: access establishment and maintenance [33,
34], provision of dialysis services [34], erythropoiesis-sti-
mulating agents (ESA) [35, 36], patient monitoring [34],
all-cause hospitalisation [34, 37], transportation to and
from dialysis clinics [38–40] and kidney transplantation
costs [41, 42]. It is assumed that these elements capture the
principal costs associated with the treatment of ESRD
patients. Detailed cost input data (year of valuation
2013–2014) are shown in Table 2.
2.4 Cost-Effectiveness Analysis
For the base case analysis, three alternative scenarios
with 39, 50 and 5 % PD respectively were compared
with the current clinical practice of 22 %. In line with
current UK Treasury guidance, future costs and benefits
were discounted at an annual rate of 3.5 % [13]. The
main outcome measure was the ICER, the cost per
incremental QALY. Given the available survival data
and in line with previous economic evaluations in ESRD
[6, 43, 44], 5- and 10-year time horizons were presented
as main results.
2.5 Sensitivity Analyses
One-way sensitivity analyses were performed to assess
how sensitive results were to changes in model parameters.
All model parameters were individually varied between a
minimum and maximum value and their impact on model
results recorded. Variables were altered according to pub-
lished ranges (available for transplant graft failure rates
[22], certain switching rate inputs [45] and utility values
[28]) or by ±25 % for those variables without such
information. The following parameters were analysed: all-
cause hospitalisation rates, transition probabilities, survival
parameters, costs, transplant and graft failure rates, and
utilities. Parameter ranges are shown in Tables 1, 2.
Results are presented in the form of a tornado diagram.
Probabilistic sensitivity analysis (PSA) was also con-
ducted. In PSA, model parameters are assigned appropriate
statistical distributions and are permitted to vary according
to those distributions. Running a large number of simula-
tions allows a more accurate assessment of the effect of
parameter uncertainty on model results. Distributions
assigned to parameters in the PSA are shown in Tables 1
and 2. PSA results are presented in the form of a cost-
effectiveness plane scatter diagram and a cost-effectiveness
acceptability curve (CEAC).
Further sensitivity analyses for different time horizons
beyond 10 years, including 15, 20, 30 and 40 years, were
also conducted to test the robustness of the model
conclusions.
3 Results
Table 3 presents the results for the cost-effectiveness
model with regard to total costs, QALYs and the ICER. For
the reference scenario, total discounted costs and QALYs
per patient over 5- and 10-year time horizons were £96,307
and 2.104 and £133,339 and 3.301, respectively. Assuming
an increase in PD to 39 % of all dialysis use in incident
dialysis patients (Scenario 1), the cost difference versus the
reference scenario was a saving of £3,180 over 5 years and
£4,102 over 10 years per patient, with a small increase in
QALYs of 0.017 over 5 years and 0.020 over 10 years per
patient. Scenario 1 was dominant, providing better out-
comes at lower costs. When assuming an increase in PD to
50 % of all dialysis use in incident dialysis patients (Sce-
nario 2), the cost difference versus the reference scenario
was a saving of £5,238 over 5 years and £6,758 over
10 years per patient. In this case, the difference in QALYs
was a small increase of 0.029 over 5 years and 0.033 over
10 years per patient; hence Scenario 2 was also dominant.
If the use of PD in incident dialysis patients decreases to
5 % (Scenario 3), the cost difference versus the reference
scenario was an increase of £3,179 over 5 years and £4,098
over 10 years per patient. The difference in QALYs was a
small decrease of 0.017 over 5 years and 0.020 over
10 years per patient; in this case, Scenario 3 was dominated
(associated with worse outcomes and higher costs). Results
over longer time horizons of 15–40 years were consistent
with the 10 year results.
3.1 Sensitivity Analyses
As the costing report associated with NICE CG125 cites
39 % PD as the optimal level [12], sensitivity analysis
results are only reported for Scenario 1 (39 % PD) versus
the reference scenario. Figure 2 shows the results of the
one-way sensitivity analysis for scenario 1 at 10 years. As
can be seen from the x-axis, the net benefit never falls
below zero, indicating that Scenario 1 remained cost-
effective relative to the reference scenario over the range of
variables tested [46]. The net benefit calculation assigns a
monetary value to the incremental health gains (QALYs)
achieved. The incremental cost of achieving these gains is
subtracted from their monetary value to give the net ben-
efit. If the resulting figure is positive, this indicates that the
monetary value of the health gains exceeds the incremental
cost and the intervention is considered to be cost-effective.
Likewise, if the net benefit is negative then the intervention
is not considered to be cost-effective. To be conservative,
the willingness-to-pay value used for the calculation of the
net benefit was £20,000. The model is mostly sensitive to
costs and survival parameters—changes in the values of
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Table 2 Cost input data
Parameter Value (range) Data sources
HD-related costs
Vascular access cost £1,287 (£965–£1,609) PbR tariff 2013–2014 [34]
ICHD cost per session
Catheter access £121 (£92–£154) PbR tariff 2013–2014 [34]
AV fistula/graft access £152 (£115–£191)
Weighted £147 Breakdown based on the target percentage set by the best practice
tariff for 2013–2014 [60]
Home HD cost per week £456 (£342–£570) PbR tariff 2013–2014 [34]
HD conventional ESA cost
Dose (units/week) 6,306 (4,730–7,883) Rao [61]
ESA cost per 1,000 units £5.09 (£3.82–£6.36) BNF No. 67 [35]
Cost per HD hospitalisation £1,887 (£1,415–£2,359) Event costs from the PbR tariff 2013–2014 [34]. Event numbers from
the National Schedule of Reference Costs 2011–2012 [37]
PD-related costs
Peritoneal access costs (PD specific) £1,233 (£854–£1,423) PbR tariff 2013–2014 [34]
PD cost per day
APD £52 (£39–£65) PbR tariff 2013–2014 [34]
CAPD £46 (£35–£58)
PD ESA cost (all sub-modalities)
Dose (units/week) 2,933 (2,200–3,666) Rao [61]
ESA cost per 1,000 units £5.09 (£3.82–£6.36) BNF No. 67 [35]
Cost per PD hospitalisation £1,504 (£1,128–£1,880) Event costs from the PbR tariff 2013–2014 [34]. Event numbers from
the National Schedule of Reference Costs 2011–2012 [37]
Overall (common) costs
Transplant cost
Donor after brain death £19,804 (£14,853–£24,755) National Schedule of Reference Costs 2012–2013 [42]
Donor after cardiac death £16,580 (£12,435–£20,725)
Living donor £18,640 (£13,980–£23,300)
Weighted £18,579 Breakdown based on the NHS Blood and Transplant Activity Report
for 2012–2013 [59]
Post-transplant medication costs £11,137 (£8,352–£13,921) NHS Kidney Care report [41]
Monitoring costs
Single professional £132 (£99–£165) PbR tariff 2013–2014 [34]
Multi professional £247 (£185–£309)
Weighted £190 Equal weighting assumed
Transport cost per visit £44 (£33–£55)§ NHS Law on tariffs [38]
National Schedule of Reference Costs 2009–2010 [39]
National Schedule of Reference Costs 2010–2011 [62]
National Kidney Care Audit, Patient Transport Survey 2010 [40]
APD automated peritoneal dialysis, AV arteriovenous, CAPD continuous ambulatory peritoneal dialysis, ESA erythropoiesis-stimulating agents,
HD haemodialysis, ICHD in-centre haemodialysis, PbR payment by results, PD peritoneal dialysis
 All cost parameters are assigned gamma distributions for PSA; this reflects best practice. The gamma distribution is constrained to non-
negative values and can be used to represent uncertainty in cost parameters
 Patients on each modality are assumed to receive two monitoring visits/year
§ The weighted average cost of hospital-arranged transport was estimated to be £69. However, it is estimated that 36 % of transport visits are
paid for by the patient; therefore, the overall weighted average cost per transport visit reflects this
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these parameters have the biggest impact on the overall
result.
Figure 3 shows the results of the PSA for Scenario 1
(i.e. 39 % of incident patients on PD). The cost-effective-
ness plane represents the results of 1,000 simulations in
terms of incremental costs and QALYs. Scenario 1 was less
expensive than the reference scenario in 96.3 % of simu-
lations, 95th percentile interval for incremental costs
(-£8,585, £202). However, in 38 % of simulations Sce-
nario 1 was less costly but also less effective (i.e. it falls in
the South-West quadrant), 95th percentile interval for
incremental QALYs (-0.088, 0.124). The CEAC presents
the probability that Scenario 1 was cost-effective versus the
reference scenario at different values of the willingness-to-
pay threshold (up to £50,000). The probability is based on
the proportion of simulations in which the net benefit is
positive. The results demonstrate that the probability that
Scenario 1 was cost-effective at each willingness-to-pay
threshold value of 0–£50,000 was almost 100 %.
4 Discussion
The results of this study suggest that increasing PD use
among new patients with ESRD initiating dialysis from the
current 22 % to either 39 or 50 % would be cost-effective,
associated with reduced costs and modest improvements in
health outcomes. Reducing PD use to 5 %, however, would
result in higher costs and worse outcomes. The range of
QALY differences observed in the sensitivity analyses
reflects the clinical uncertainty surrounding the relative
effectiveness of PD and HD; thus, dominance cannot be
presumed. However, the cost savings associated with
increasing PD use to 39 % of incident dialysis patients are
such that one can be confident that it will be deemed cost-
effective. Results were also considered for longer time
horizons of 15, 20, 30 and 40 years and were found to be
consistent with the results for 10 years.
These findings are consistent with prior studies on this
topic. The cost-effectiveness analysis conducted by NICE
Table 3 Results of the effect of varying the proportion of incident patients on PD showing the total costs, QALYs per patient and the ICER
Total costs (£) QALYs ICER (vs. reference scenario)
Reference scenario (5 years) 96,307 2.104 –
Scenario 1 (39 % PD) 93,127 2.121 Dominant*
Scenario 2 (50 % PD) 91,069 2.133 Dominant*
Scenario 3 (5 % PD) 99,486 2.087 Dominated**
Reference scenario (10 years) 133,339 3.301 –
Scenario 1 (39 % PD) 129,237 3.321 Dominant*
Scenario 2 (50 % PD) 126,580 3.334 Dominant*
Scenario 3 (5 % PD) 137,436 3.281 Dominated**
For the following time horizons, equal survival was assumed after 10 years
Reference scenario (15 years) 151,531 4.035 –
Scenario 1 (39 % PD) 146,982 4.054 Dominant*
Scenario 2 (50 % PD) 144,035 4.067 Dominant*
Scenario 3 (5 % PD) 156,074 4.016 Dominated**
Reference scenario (20 years) 161,864 4.499 –
Scenario 1 (39 % PD) 157,088 4.518 Dominant*
Scenario 2 (50 % PD) 153,993 4.530 Dominant*
Scenario 3 (5 % PD) 166,635 4.479 Dominated**
Reference scenario (30 years) 172,255 4.987 –
Scenario 1 (39 % PD) 167,256 5.006 Dominant*
Scenario 2 (50 % PD) 164,018 5.019 Dominant*
Scenario 3 (5 % PD) 177,248 4.968 Dominated**
Reference scenario (40 years) 176,465 5.189 –
Scenario 1 (39 % PD) 171,378 5.208 Dominant*
Scenario 2 (50 % PD) 168,082 5.220 Dominant*
Scenario 3 (5 % PD) 181,546 5.169 Dominated**
ICER incremental cost effectiveness ratio, QALY quality-adjusted life year
* Better outcomes, lower costs
** Worse outcomes, higher costs
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analysed the prevalent population in order to determine
whether the proportion of patients on PD should be
increased in England and Wales [47]. Compared with the
reference scenario (Hospital HD 47 %, Satellite HD 33 %,
HHD 2 %, CAPD 14 %, APD 4 %), increasing PD use
(Hospital HD 8.5 %, Satellite HD 49 %, HHD 9.5 %,
CAPD 20 %, APD 13 %) resulted in reduced costs (ref-
erence scenario £130,234; PD scenario £120,200) and
better QALYs (reference scenario 3.77; PD scenario 3.87)
and was dominant at 10 years. It has been reported that
increasing use of PD from current levels (approximately
15 %) to 39 % among prevalent patients is cost-effective
and could realise annual savings of approximately £20
million nationally [12]. When the NICE scenario was tes-
ted as closely as possible in the current model using the
prevalent population (data inputs not shown), it was found
that increasing PD also resulted in reduced costs (reference
scenario £138,606; PD scenario £132,969) and better
Fig. 2 One-way sensitivity analysis for Scenario 1 (PD 39 %; ICHD
conventional 61 %): Tornado diagram for the top 15 parameters—
10 year results. The tornado diagram shows the sensitivity of the net
benefit (NB) to changes in the model parameters. The value of each
parameter in the model was replaced in turn, first with its lowest
plausible value, then its highest plausible value; the resulting
variation in the NB permits the identification of parameters that are
key drivers of the model outcome. Parameters having the most impact
on the NB are shown at the top of the tornado diagram with the
biggest bars and those that have the least impact are at the bottom of
the diagram with the smallest bars. To be conservative, a willingness-
to-pay value of £20,000/QALY was used for the calculation of the
NB. APD automated peritoneal dialysis, AV arteriovenous, CAPD
continuous ambulatory peritoneal dialysis, HD haemodialysis, HHD
home haemodialysis, HR hazard ratio, ICHD in-centre haemodialysis,
PD peritoneal dialysis, SAT satellite unit
Fig. 3 Probabilistic sensitivity analysis for Scenario 1 (PD 39 %;
ICHD conventional 61 %)—10-year results. Model parameters are
assigned suitable statistical distributions and are permitted to vary
according to those distributions. The cost-effectiveness plane shows
the results of 1,000 simulations plotted on a scatter plot of
incremental costs and incremental effectiveness [quality-adjusted life
years (QALY)] for Scenario 1 versus the reference scenario. The cost-
effectiveness acceptability curve presents the probability that Sce-
nario 1 (39 % PD) is cost-effective versus the reference scenario at
different values of the willingness-to-pay threshold
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QALYs (reference scenario 3.38; PD scenario 3.43) as well
as a dominant ICER versus the reference scenario. How-
ever, the decision to focus on incident dialysis patients
rather than prevalent dialysis patients is in response to the
perceived benefits of starting incident patients on PD; these
include improved early survival and better preservation of
residual renal function [46, 48, 49].
Studies from other countries have also reported that
increasing PD use in incident patients with ESRD requiring
dialysis is cost-effective [45, 50, 51]. To the authors’
knowledge, this is the only study that has looked at
increasing the proportion of PD use among incident
patients from the perspective of the UK NHS. Neil et al.
used a budget impact analysis to estimate the country-
specific, 5-year financial impact on total dialysis costs,
assuming utilisation shifts from HD to PD in the prevalent
population in two high-income, three upper-middle-income
and three lower-middle-income countries [52]. This study
found that increasing PD rates could be significantly cost-
saving compared with HD in all the studied countries,
including the UK.
The key strengths of the current analysis are first that the
model structure was informed by previous economic
evaluations in ESRD including the analysis conducted by
NICE in relation to CG 125—peritoneal dialysis [10].
Second, model assumptions and inputs were validated at a
clinical advisory board and with a UK-based nephrology
key opinion leader who had been involved in both inpatient
and outpatient NHS renal services and was involved in the
NICE appraisals of HD and PD.
Although the best-available published evidence was
used to model costs and benefits associated with increasing
PD use among incident patients with ESRD requiring
dialysis, the analysis has several limitations. First, some
data may not be completely representative of current
clinical practice in the UK, as some model inputs were
derived from other countries where clinical practice might
be different. Survival, for example, is based on European
data in which UK patients represent 20 % of all incident
patient counts [17]. In order to facilitate future research and
economic evaluations in the UK, it would be very valuable
to have more comprehensive UK-based clinical and epi-
demiological data, including long-term comparative sur-
vival data for PD vs. ICHD. Second, the current data are
only applicable to adult patients who are suitable and
willing candidates for PD. Patient suitability is based on
NICE clinical guidelines. Third, to calculate the number of
hospitalisations in subsequent years versus the first year,
data from a study published by Arora in 2000 were used—
more recent data were not identified [32]. This study sug-
gested that the rate of hospitalisations in PD patients did
not drop in subsequent years while in HD patients the rate
dropped by 30 %. Since PD technology has improved
significantly in the interim, the number of hospitalisations
in PD patients may be overestimated. Thus, the results may
be biased in favour of HD. Fourth, given the payer per-
spective of the analysis, indirect costs related to working
days lost, direct out-of-pocket costs to patients and carers
were not incorporated. Fifth, with regard to other medica-
tion costs, there is currently a lack of evidence demon-
strating that these costs differ between the different
treatment modalities within the UK. Finally, data avail-
ability did not permit the consideration of the relative
clinical efficacy of APD versus CAPD. Therefore these
conclusions relate to PD in general as conducted in the UK.
This analysis does not advocate one kind of PD treatment
over another.
The present study may have important implications for
policymakers. As part of extensive healthcare reform in the
UK, the QIPP programme aims to improve the quality and
delivery of NHS care while making efficiency savings. For
example, one aim is to ‘‘reduce expensive hospital
admissions by: getting patients more involved in managing
their own conditions; where possible treating more patients
closer to home’’ [53]. The current results show that PD is
associated with quality improvements and cost savings
compared to conventional ICHD. The increased use of PD
could make a significant contribution to the target of
achieving £20 billion efficiency savings by 2015 while
improving the quality of a patient-focussed health service.
In summary, this study suggests that using PD in line
with NICE recommendations may be a cost-effective
method of treating incident ESRD patients requiring dial-
ysis. It is acknowledged also that there are some limitations
associated with this analysis due to many of the model
inputs being based on data not specifically relating to the
UK. Additionally, the results of the PSA show that there is
uncertainty regarding the clinical benefits of PD over other
dialysis modalities. Further research is therefore warranted
into the clinical comparative effectiveness of PD versus
HD. However, this study suggests that, from a UK payer
perspective, increasing the proportion of patients on PD
could lead to cost reductions while also improving clinical
outcomes and QoL, thus alleviating the burden to the
patient. The results suggest that policies encouraging the
use of PD as the first dialysis option would help support
implementation of the NHS QIPP agenda and that quality
of care could be improved with reduced resource use.
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